Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index. FIDELITY Post Hoc Analysis
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rossing, Peter | |
| dc.contributor.author | Birkenfeld, Andreas L. | |
| dc.contributor.author | Fioretto, Paola | |
| dc.contributor.author | McGill, Janet B. | |
| dc.contributor.author | Anker, Stefan D. | |
| dc.contributor.author | Pitt, Bertram | |
| dc.contributor.author | Rohwedder, Katja | |
| dc.contributor.author | Scalise, Andrea | |
| dc.contributor.author | Scott, Charlie | |
| dc.contributor.author | Filippatos, Gerasimos | |
| dc.contributor.author | FIDELIO-DKD | |
| dc.contributor.author | FIGARO-DKD | |
| dc.date.accessioned | 2025-06-12T15:22:08Z | |
| dc.date.available | 2025-06-12T15:22:08Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Background Frailty is associated with a higher risk of adverse outcomes. It is believed that people with a higher frailty index (FI) may be less tolerant to new treatments, often leading to inappropriate prescribing. This post hoc analysis of FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease (FIDELIO-DKD) and FIGARO-DKD Trial program analysis, a prespecified, pooled analysis of the FIDELIO-DKD and FIGARO-DKD phase 3 clinical trials, investigated the efficacy and safety of finerenone versus placebo according to baseline FI. Methods Between September 2015 and October 2018, 12,990 people with CKD and type 2 diabetes receiving the maximum tolerated dose of a renin-angiotensin system inhibitor were randomized to receive finerenone 10 or 20 mg once daily or placebo. Baseline FI was calculated using the Rockwood cumulative deficit approach including 30 clinical characteristics. Primary efficacy outcomes included a kidney (kidney failure, sustained decrease of $57% in eGFR, or kidney-related death) and a cardiovascular (CV) composite outcome (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure). Changes in urine albumin-to-creatinine ratio and eGFR were measured across the study period. Results Overall, kidney and CV event rates increased with increasing frailty. Finerenone reduced the risk of primary kidney and CV composite outcomes irrespective of baseline frailty (P interaction 5 0.93 and 0.35, respectively). Compared with placebo, finerenone also demonstrated significant reductions in urine albumin-to-creatinine ratio across all frailty subgroups (P , 0.01 for all visits) and significant attenuation of eGFR decline from baseline to month 48 in the three most frail quartiles (.Q1 to #Q2, P 5 0.001; .Q2 to #Q3, P , 0.001; .Q3, P , 0.001, respectively). The incidence of serious adverse events and hyperkalemia increased with increasing frailty in both treatment arms. Conclusions Finerenone reduced the risk of CV and kidney events in people with CKD and type 2 diabetes versus placebo irrespective of baseline frailty status. | eng |
| dc.format.mimetype | ||
| dc.identifier.citation | Rossing, Peter1,2; Birkenfeld, Andreas L.3,4,5; Fioretto, Paola6; McGill, Janet B.7; Anker, Stefan D.8,9; Pitt, Bertram10; Rohwedder, Katja11; Scalise, Andrea12; Scott, Charlie13; Filippatos, Gerasimos14; on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis. Clinical Journal of the American Society of Nephrology ():10.2215/CJN.0000000700, May 2, 2025. | DOI: 10.2215/CJN.0000000700 | |
| dc.identifier.doi | https://doi.org/10.2215/CJN.0000000700 | |
| dc.identifier.issn | 1555905X (Electrónico) | |
| dc.identifier.issn | 15559041 (Impreso) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16670 | |
| dc.identifier.url | https://journals.lww.com/cjasn/fulltext/9900/finerenone_and_clinical_outcomes_in_ckd_and_type_2.611.aspx | |
| dc.language.iso | eng | |
| dc.publisher | American Society of Nephrology | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Clinical Journal of the American Society of Nephrology | eng |
| dc.source | CJASN | spa |
| dc.subject.keywords | CKD | eng |
| dc.subject.keywords | Diabetes | eng |
| dc.title | Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index. FIDELITY Post Hoc Analysis | eng |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Sciacchitano S, Carola V, Nicolais G, et al. To be frail or not to be frail: this is the question - a critical narrative review of frailty. J Clin Med. 2024;13(3):721. doi:10.3390/jcm13030721 | eng |
| dcterms.references | Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021;12(5):1227–1247. doi:10.1007/s13300-021-01035-9 | eng |
| dcterms.references | Vart P, Butt JH, Jongs N, et al. Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. J Gerontol A Biol Sci Med Sci. 2024;79(2):glad181. doi:10.1093/gerona/glad181 | eng |
| dcterms.references | Walker SR, Gill K, Macdonald K, et al. Association of frailty and physical function in patients with non-dialysis CKD: a systematic review. BMC Nephrol. 2013;14:228. doi:10.1186/1471-2369-14-228 | eng |
| dcterms.references | Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365–1375. doi:10.1016/S0140-6736(19)31786-6 | eng |
| dcterms.references | Butt JH, Jhund PS, Belohlávek J, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146(16):1210–1224. doi:10.1161/circulationaha.122.061754 | eng |
| dcterms.references | Austad SN, Fischer KE. Sex differences in lifespan. Cell Metab. 2016;23(6):1022–1033. doi:10.1016/j.cmet.2016.05.019 | eng |
| dcterms.references | Roshanravan B, Khatri M, Robinson-Cohen C, et al. A prospective study of frailty in nephrology-referred patients with CKD. Am J Kidney Dis. 2012;60(6):912–921. doi:10.1053/j.ajkd.2012.05.017 | eng |
| dcterms.references | Mansur HN, Colugnati FA, Grincenkov FR, Bastos MG. Frailty and quality of life: a cross-sectional study of Brazilian patients with pre-dialysis chronic kidney disease. Health Qual Life Outcomes. 2014;12:27. doi:10.1186/1477-7525-12-27 | eng |
| dcterms.references | Hannan M, Chen J, Hsu J, et al. Frailty and cardiovascular outcomes in adults with CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2024;83(2):208–215. doi:10.1053/j.ajkd.2023.06.009 | eng |
| dcterms.references | Zhang F, Wang H, Bai Y, Zhang Y, Huang L, Zhang H. Prevalence of physical frailty and impact on survival in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2023;24(1):258. doi:10.1186/s12882-023-03303-1 | eng |
| dcterms.references | Chowdhury R, Peel NM, Krosch M, Hubbard RE. Frailty and chronic kidney disease: a systematic review. Arch Gerontol Geriatr. 2017;68:135–142. doi:10.1016/j.archger.2016.10.007 | eng |
| dcterms.references | Guerville F, de Souto Barreto P, Taton B, et al. Estimated glomerular filtration rate decline and incident frailty in older adults. Clin J Am Soc Nephrol. 2019;14(11):1597–1604. doi:10.2215/CJN.03750319 | eng |
| dcterms.references | Sinclair AJ, Abdelhafiz AH, Rodríguez-Mañas L. Frailty and sarcopenia - newly emerging and high impact complications of diabetes. J Diabetes Complications. 2017;31(9):1465–1473. doi:10.1016/j.jdiacomp.2017.05.003 | eng |
| dcterms.references | Lavan AH, Gallagher P, Parsons C, O'Mahony D. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. Age Ageing. 2017;46(4):600–607. doi:10.1093/ageing/afx005 | eng |
| dcterms.references | O'Connor MN, Gallagher P, O'Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29(6):437–452. doi:10.2165/11632610-000000000-00000 | eng |
| dcterms.references | Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–484. doi:10.1093/eurheartj/ehab777 | eng |
| dcterms.references | Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi:10.1056/NEJMoa2025845 | eng |
| dcterms.references | Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. doi:10.1056/NEJMoa2110956 | eng |
| dcterms.references | Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):345–356. doi:10.1159/000503712 | eng |
| dcterms.references | Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333–344. doi:10.1159/000503713 | eng |
| dcterms.references | Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62(7):722–727. doi:10.1093/gerona/62.7.722 | eng |
| dcterms.references | Vonesh E, Tighiouart H, Ying J, et al. Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med. 2019;38(22):4218–4239. doi:10.1002/sim.8282 Cited Here | Google Scholar | eng |
| dcterms.references | Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–S314. doi:10.1016/j.kint.2023.10.018 | eng |
| dcterms.references | Hubbard RE, O'Mahony MS, Woodhouse KW. Medication prescribing in frail older people. Eur J Clin Pharmacol. 2013;69(3):319–326. doi:10.1007/s00228-012-1387-2 | eng |
| dcterms.references | Malik ME, Butt JH, Strange JE, et al. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longev. 2023;4(10):e552–e560. doi:10.1016/s2666-7568(23)00164-2 | eng |
| dcterms.references | Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920 | eng |
| dcterms.references | Oshima M, Jardine MJ, Agarwal R, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021;99(4):999–1009. doi:10.1016/j.kint.2020.10.042 | eng |
| dcterms.references | Jongs N, Chertow GM, Greene T, et al. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022;33(11):2094–2107. doi:10.1681/ASN.2022030306 | eng |
| dcterms.references | Bakris GL, Weir MR. Initial drops in glomerular filtration rate with certain drug classes retard kidney disease progression. Am J Nephrol. 2022;53(7):513–515. doi:10.1159/000524890 | eng |
| dcterms.references | Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282–287. doi:10.1038/ki.2011.79 | eng |
| dcterms.references | American Diabetes Association Professional Practice Committee. 13. Older adults: standards of care in diabetes-2024. Diabetes Care. 2024;47(suppl 1):S244–S257. doi:10.2337/dc24-S013 | eng |
| dcterms.references | Spiers GF, Kunonga TP, Hall A, et al. Measuring frailty in younger populations: a rapid review of evidence. BMJ Open. 2021;11(3):e047051. doi:10.1136/bmjopen-2020-047051 | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |